New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deep and Sustained Undetectable Minimal Residual Disease Outcomes in First-line Chronic Lymphocytic Leukaemia
- EMEA Innovative Medicine
- New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deep and Sustained Undetectable Minimal Residual Disease Outcomes in First-line Chronic Lymphocytic Leukaemia
New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deep and Sustained Undetectable Minimal Residual Disease Outcomes in First-line Chronic Lymphocytic Leukaemia
- X (Twitter)
Copy link